Guardant Health, Inc. (NASDAQ:GH) Stock Rated “Moderate Buy” by Wall Street Brokerages

Guardant Health, Inc. (NASDAQ:GH – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-six analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, twenty-four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $191.48.

GH has been the topic of several research analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research note on Wednesday. Barclays lifted their target price on shares of Guardant Health from $200.00 to $220.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. UBS Group increased their price target on Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. BTIG Research lifted their price objective on Guardant Health from $195.00 to $210.00 and gave the company a “buy” rating in a research report on Tuesday, October 27th. Finally, Royal Bank Of Canada boosted their price objective on Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st.

Read Our Latest Research Report on GH

Key Stories Impacting Guardant Health

Here are a few of the latest stories about GH:

  • Positive Sentiment: Guardant launched Guardant Reveal Ultra in U.S. clinics, a molecular residual disease platform for solid tumors designed to detect cancer at a sensitivity of one part per million. The launch could expand the company’s testing offering and support future growth. Guardant Health launches Reveal Ultra
  • Positive Sentiment: Stephens reaffirmed its “overweight” rating and set a $210 price target, signaling confidence in the stock’s prospects. Stephens stock recommendations
  • Positive Sentiment: A recent report focused on raised guidance, which may bolster expectations for the company’s business outlook. What raised guidance means for shareholders

Insider Buying and Selling

In related news, Director Steve E. Krognes sold 6,674 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $175.74, for a total value of $1,172,888.76. Following the completion of the transaction, the director directly owned 7,906 shares in the company, valued at approximately $1,389,400.44. The trade was a 45.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Darya Chudova sold 7,738 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total transaction of $1,377,364.00. Following the sale, the chief technology officer directly owned 70,635 shares of the company’s stock, valued at $12,573,030. This represents a 9.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 19,566 shares of company stock valued at $3,320,185 over the last 90 days. Company insiders own 5.60% of the company’s stock.

Institutional Trading of Guardant Health

Several institutional investors and hedge funds have recently bought and sold shares of GH. Financial Network Wealth Advisors LLC increased its position in shares of Guardant Health by 17.2% in the third quarter. Financial Network Wealth Advisors LLC now owns 423 shares of the company’s stock worth $75,000 after purchasing an additional 62 shares during the period. Yousif Capital Management LLC lifted its position in Guardant Health by 6.2% during the third quarter. Yousif Capital Management LLC now owns 1,587 shares of the company’s stock worth $283,000 after purchasing an additional 93 shares during the period. Allworth Financial LP lifted its position in Guardant Health by 12.4% during the second quarter. Allworth Financial LP now owns 1,072 shares of the company’s stock worth $161,000 after purchasing an additional 118 shares during the period. GAMMA Investing LLC lifted its position in Guardant Health by 14.5% during the second quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock worth $145,000 after purchasing an additional 122 shares during the period. Finally, Slow Capital Inc. grew its stake in Guardant Health by 0.3% during the third quarter. Slow Capital Inc. now owns 52,683 shares of the company’s stock worth $9,397,000 after buying an additional 136 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

NASDAQ:GH opened at $145.83 on Monday. The company has a market capitalization of $19.73 billion, a P/E ratio of -39.63 and a beta of 1.67. The stock’s 50 day moving average price is $167.08 and its 200 day moving average price is $133.80. Guardant Health has a 52 week low of $74.55 and a 52 week high of $191.05.

Guardant Health (NASDAQ:GH – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.46. The firm had revenue of $360.98 million during the quarter, compared to analyst estimates of $350.72 million. During the same quarter in the previous year, the business posted ($0.74) earnings per share. The business’s quarterly revenue was up 36.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Guardant Health will post -3.28 earnings per share for the current fiscal year.

About Guardant Health

(Get Free Report)

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

Recommended Stories

Analyst Recommendations for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.